Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3597-3604

  Lucumi, Edinson ^a   Darling, Claire ^b   Jo, Hyunil ^b   Napper, Andrew D ^a,d   Chandramohanadas, Rajesh ^b   Fisher, Nicholas ^c   Shone, Alison E ^c   Jing, Huiyan ^a   Ward, Stephen A ^c   Biagini, Giancarlo A ^c   DeGrado, William F ^b   Diamond, Scott L ^a   Greenbaum, Doron C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; AMPEROZIDE; ANTIMALARIAL AGENT; ARTESUNATE; ATOVAQUONE; CHLOROQUINE; DIHYDROARTEMISININ; DOXORUBICIN; LUCIFERASE; MEFLOQUINE; ZOLANTIDINE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 77956120375     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00431-10     Document Type: Article

References (36)

1. Baniecki, M. L., D. F. Wirth, and J. Clardy. 2007. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob. Agents Chemother. 51:716-723.
2. Biagini, G. A., N. Fisher, N. Berry, P. A. Stocks, B. Meunier, D. P. Williams, R. Bonar-Law, P. G. Bray, A. Owen, P. M. O'Neill, and S. A. Ward. 2008. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol. Pharmacol. 73:1347-1355.
3. Biagini, G. A., P. Viriyavejakul, M. O'Neill, P. G. Bray, and S. A. Ward. 2006. Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob. Agents Chemother. 50:1841-1851.
4. Burckhalter, J. H., F. H. Tendick, E. M. Jones, P. A. Jones, W. F. Holcomb, and A. L. Rawlins. 1948. Aminoalkylphenols as antimalarials. II. (Heterocyclic-amino)-α-amino-o-cresols. The synthesis of camoquin. J. Am. Chem. Soc. 70:1363-1373.
5. Burland, W. L., W. A. Duncan, T. Hesselbo, J. G. Mills, P. C. Sharpe, S. J. Haggie, and J. H. Wyllie. 1975. Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br. J. Clin. Pharmacol. 2:481-486.
6. Calderwood, M. S., L. Gannoun-Zaki, T. E. Wellems, and K. W. Deitsch. 2003. Plasmodium falciparum var genes are regulated by two regions with separate promoters, one upstream of the coding region and a second within the intron. J. Biol. Chem. 278:34125-34132.
7. Chong, C. R., X. Chen, L. Shi, J. O. Liu, and D. J. Sullivan. 2006. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2:415-416.
8. Cui, L., J. Miao, J. Wang, Q. Li, and L. Cui. 2008. Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter. Exp. Parasitol. 120:80-87.
9. Desjardins, R. E., C. J. Canfield, J. D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
10. Duncan, W. G., and D. W. Henry. 1969. N-Dialkylaminoalkylbiphenylamines as antimalarial and antischistosomal agents. J. Med. Chem. 12:25-29.
11. Fisher, N., A. J. Warman, S. A. Ward, and G. A. Biagini. 2009. Chapter 17 type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays. Methods Enzymol. 456:303-320.
12. Fisher, N., C. K. Castleden, I. Bourges, G. Brasseur, G. Dujardin, and B. Meunier. 2004. Human disease-related mutations in cytochrome b studied in yeast. J. Biol. Chem. 279:12951-12958.
13. Fisher, N., P. G. Bray, S. A. Ward, and G. A. Biagini. 2007. The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends Parasitol. 23:305-310.
14. Frearson, J. A., P. G. Wyatt, I. H. Gilbert, and A. H. Fairlamb. 2007. Target assessment for antiparasitic drug discovery. Trends Parasitol. 23:589-595.
15. Fry, M., and M. Pudney. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy- 1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43:1545-1553.
16. Guiguemde, W. A., A. A. Shelat, D. Bouck, S. Duffy, G. J. Crowther, P. H. Davis, D. C. Smithson, M. Connelly, J. Clark, F. Zhu, M. B. Jimenez-Diaz, M. S. Martinez, E. B. Wilson, A. K. Tripathi, J. Gut, E. R. Sharlow, I. Bathurst, F. El Mazouni, J. W. Fowble, I. Forquer, P. L. McGinley, S. Castro, I. Angulo-Barturen, S. Ferrer, P. J. Rosenthal, J. L. Derisi, D. J. Sullivan, J. S. Lazo, D. S. Roos, M. K. Riscoe, M. A. Phillips, P. K. Rathod, W. C. Van Voorhis, V. M. Avery, and R. K. Guy. 2010. Chemical genetics of Plasmodium falciparum. Nature 465:311-315.
17. Inglese, J., R. L. Johnson, A. Simeonov, M. Xia, W. Zheng, C. P. Austin, and D. S. Auld. 2007. High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3:466-479.
18. Iversen, P. W., B. J. Eastwood, G. S. Sittampalam, and K. L. Cox. 2006. A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. J. Biomol. Screen. 11:247-252.
19. Johnson, J. D., R. A. Dennull, L. Gerena, M. Lopez-Sanchez, N. E. Roncal, and N. C. Waters. 2007. Assessment and continued validation of the MSF assay for use in malaria drug screening. Antimicrob. Agents Chemother. 51:1926-1933.
20. Korsinczky, M., N. Chen, B. Kotecka, A. Saul, K. Rieckmann, and Q. Cheng. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44:2100-2108.
21. Kuboyama, M., F. C. Yong, and T. E. King. 1972. Studies on cytochrome oxidase. 8. Preparation and some properties of cardiac cytochrome oxidase. J. Biol. Chem. 247:6375-6383.
22. Kyriakis, S. C., K. Martinsson, N. G. Olsson, and A. Bjork. 1990. Thin sow syndrome (TSS): the effect of amperozide. Br. Vet. J. 146:463-467.
23. Li, Q., L. Gerena, L. Xie, J. Zhang, D. Kyle, and W. Milhous. 2007. Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. Cytometry A 71:297-307.
24. Mueller, R., M. Huerzeler, and C. Boss. 2003. Synthesis of plasmepsin II inhibitors-potential antimalarial agents. Molecules 8:556-564. (Pubitemid 38982525)
25. Nalwalk, J. W., J. E. Koch, K. E. Barke, R. J. Bodnar, and L. B. Hough. 1995. Modulation of morphine antinociception by the brain-penetrating H2 antagonist zolantidine: detailed characterization in five nociceptive test systems. Pharmacol. Biochem. Behav. 50:421-429.
26. Plouffe, D., A. Brinker, C. McNamara, K. Henson, N. Kato, K. Kuhen, A. Nagle, F. Adrian, J. T. Matzen, P. Anderson, T. Nam, N. S. Gray, A. Chatterjee, J. Janes, S. F. Yan, R. Trager, J. Caldwell, P. Schultz, Y. Zhou, and E. Wisnzeler. 2008. In silico activity profiling revels the mechanism of action of antimalarials discovered in high-throughput screen. Proc. Natl. Acad. Sci. U. S. A. 105:9059-9064.
27. Shah, P. P., M. C. Meyers, M. P. Beavers, J. E. Purvis, H. Jing, J. H. Grieses, E. R. Sharlow, D. A. Napper, D. M. Huryn, B. S. Cooperman, A. B. Smith III, and S. L. Diamond. 2008. Kinetic characterization and molecular docking of a novel, potent and selective slow-binding inhibitor of human cathepsin L. Mol. Pharmacol. 74:34-41.
28. Smilkstein, M., N. Sriwilaijaroen, J. X. Kelly, P. Wilairat, and M. Riscoe. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806.
29. Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint, and S. I. Hay. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217.
30. Snow, R. W., J. F. Trape, and K. Marsh. 2001. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 17:593-597.
31. Srivastava, I. K., J. M. Morrisey, E. Darrouzet, F. Daldal, and A. B. Vaidya. 1999. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33:704-711.
32. Stokker, G. E., A. A. Deana, S. J. deSolms, E. M. Schults, R. L. Smith, and E. J. Cragoe, Jr. 1980. 2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J. Med. Chem. 23:1414-1427.
33. Syafruddin, D., J. E. Siregar, and S. Marzuki. 1999. Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol. Biochem. Parasitol. 104:185-194.
34. Triglia, T., J. G. Menting, C. Wilson, and A. F. Cowman. 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 94:13944-13949.
35. Weisman, J. L., A. P. Liou, A. A. Shelat, F. E. Cohen, R. K. Guy, and J. L. DeRisi. 2006. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des. 67:409-416.
36. Yuan, J., R. L. Johnson, R. Huang, J. Wichterman, H. Jiang, K. Hayton, D. A. Fidock, T. E. Wellems, J. Inglese, C. P. Austin, and X.-Z. Su. 2009. Genetic mapping of targets mediation differential chemical phenotypes in Plasmodium falciparum. Nat. Chem. Biol. 5:765-771.